Marinus signs government contract worth up to $51M to advance drug candidate

Marinus signs government contract worth up to $51M to advance drug candidate

Source: 
Bizjournals
snippet: 

Marinus Pharmaceuticals (NASDAQ: MRNS) of Radnor said Monday it entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of IV ganaxolone for the treatment of refractory status epilepticus — a condition that can result from exposure to chemical weapons.